Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

Journal of Hepatology

Volumn 64, Issue 6, 2016, Pages 1224-1231

  Foster, Graham R ^a   Irving, William L ^b   Cheung, Michelle C M ^c   Walker, Alex J ^d   Hudson, Benjamin E ^e   Verma, Suman ^f   McLauchlan, John ^g   Mutimer, David J ^h   Brown, Ashley ⁱ   Gelson, William T H ^j   MacDonald, Douglas C ^k   Agarwal, Kosh ^f  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g MRC UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH   (United Kingdom)

^h QUEEN ELIZABETH HOSPITAL   (United Kingdom)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

^j CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Daclatasvir; Decompensated cirrhosis; Hepatitis C virus; Ledipasvir; MELD score; Sofosbuvir

Indexed keywords

DACLATASVIR; LEDIPASVIR; RIBAVIRIN; SERUM ALBUMIN; SODIUM; SOFOSBUVIR; ANTIVIRUS AGENT;

ACUTE KIDNEY FAILURE; ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SODIUM BLOOD LEVEL; TREATMENT OUTCOME; VIRAL CLEARANCE; COMPLICATION; LIVER CIRRHOSIS; MIDDLE AGED; OUTCOME ASSESSMENT; SUSTAINED VIROLOGIC RESPONSE; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE;

EID: 84962847001     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.01.029     Document Type: Article

References (15)

1. N. Afdhal, S. Zeuzem, P. Kwo, M. Choijkier, N. Gitlin, M. Puoti, and et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 2014 1889 1898
2. N. Afdhal, K.R. Reddy, D.R. Nelson, E. Lawitz, S.C. Gordon, E. Schiff, and et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Engl J Med 370 2014 1483 1493
3. F. Poordad, C. Hezode, R. Trinh, K.V. Kowdley, S. Zeuzem, K. Agarwal, and et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis N Engl J Med 370 2014 1973 1982
4. E. Lawitz, M.S. Sulkowski, R. Ghalib, M. Rodriguez-Torres, Z.M. Younossi, A. Corregidor, and et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study Lancet 384 2014 1756 1765
5. D. Dieterich, B.R. Bacon, S.L. Flamm, K.V. Kowdley, S. Milligan, N. Tsai, and et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population Hepatology 60 2014 220A
6. M. Charlton, G.T. Everson, S.L. Flamm, P. Kumar, C. Landis, R.S. Brown Jr, and et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease Gastroenterology 149 2015 649 659
7. T.M. Welzel, K. Herzer, P. Ferenci, J. Petersen, M. Gschwantler, M. Cornberg, and et al. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a multicentre compassionate use program J Hepatol 62 2015 S619 S629
8. D.R. Nelson, J.N. Cooper, J.P. Lalezari, E. Lawitz, P.J. Pockros, N. Gitlin, and et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study Hepatology 61 2015 1127 1135
9. G.R. Foster, S. Pianko, A. Brown, D. Forton, R.G. Nahass, J. George, and et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with HCV genotype 3 infection and treatment-experienced patients with cirrhosis and HCV genotype 2 infection Gastroenterology 2015 10.1053/j.gastro.2015.07.043 [Epub ahead of print]
10. A.J. van der Meer, B.J. Veldt, J.J. Feld, H. Wedemeyer, J.F. Dufour, F. Lammert, and et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593
11. A.J. van der Meer, B.J. Veldt, J.J. Feld, H. Wedemeyer, J.F. Dufour, F. Lammert, and et al. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection J Viral Hepat 21 2014 568 577
12. Z.M. Younossi, M. Stepanova, N. Afdhal, K.V. Kowdley, S. Zeuzem, L. Henry, and et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir J Hepatol 63 2015 337 345
13. J.K. Dyson, J. Hutchinson, L. Harrison, O. Rotimi, D. Tiniakos, G.R. Foster, and et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use J Hepatol 64 2016 234 238
14. M.P. Curry, J.G. O'Leary, N. Bzowej, A.J. Muir, K.M. Korenblat, J.M. Fenkel, and et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis N Engl J Med 373 2015 2618 2628
15. K.R. Reddy, M. Bourliere, M. Sulkowski, M. Omata, S. Zeuzem, J.J. Feld, and et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis Hepatology 62 2015 79 86